For research use only. Not for therapeutic Use.
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia[1][2].
Catalog Number | I043942 |
Purity | ≥95% |
Reference | [1]. McGavin JK, et al. Gemtuzumab ozogamicin. Drugs. 2001;61(9):1317-22; discussion 1323-4. [2]. Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia. National Cancer Institute. 2017 Sept. |